Drug details

Xevudy (sotrovimab injection)

type of Monoclonal Antibodies

Xevudy (sotrovimab) is a monoclonal antibody that has received Emergency Use Authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

This drug may have the following side effects:

• rash,
• diarrhea,
• infusion-related reactions, and
• hypersensitivity adverse reactions.

The following drugs are related to Xevudy, either as a replacement or used together:

• Actemra (tocilizumab injection)
• Kineret (anakinra)
• Olumiant (baricitinib tablets)
• Bebtelovimab (bebtelovimab)
• Regen-Cov (casirivimab and imdevimab injection)
• Lagevrio (molnupiravir)
• Paxlovid (nirmatrelvir tablets and ritonavir tablets)
• Veklury (remdesivir for injection)